MedTrace Logo

Long Term Treatment With L-DOPS

NCT00889135 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2016-10-18

No results posted yet for this study

Summary

This study is designed to supply L-DOPS (droxidopa) on a long term basis to patients with a genetic form of profound orthostatic hypotension, most commonly DBH deficiency. It also allows us to collect medical history information on this small population of patients that would allow us to determine if there are any complications from this type of treatment.

Conditions

  • Dopamine Beta Hydroxylase (DBH) Deficiency

Interventions

DRUG

droxidopa

Droxidopa (L-DOPS) comes in capsule form, 100 mg or 200 mg strength and is usually administered 2 - 3 times per day. It would be taken indefinitely to improve symptoms of orthostatic hypotension

Sponsors & Collaborators

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • David Robertson, M.D. · Vanderbilt University Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00889135 on ClinicalTrials.gov